Novo Nordisk A/S (NYSE:NVO) agreed on Thursday to acquire Akero Therapeutics, Inc. (NASDAQ:AKRO) focused on metabolic diseases.Transaction termsNovo Nordisk will pay $54 per share in cash (or an aggregated value of $4.7 billion) at closing.In addition, Akero shareholders will receive a non-transferable CVR entitling holders to a potential additional payment of $6 per share in cash (or an aggregated value of $0.5 billion) upon U.S. regulatory approval of EFX for the treatment of compensated cirrhosis due to ...